Alan T. Henley

1.7k total citations
12 papers, 267 citations indexed

About

Alan T. Henley is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Alan T. Henley has authored 12 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Cell Biology. Recurrent topics in Alan T. Henley's work include Biochemical and Molecular Research (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Microtubule and mitosis dynamics (2 papers). Alan T. Henley is often cited by papers focused on Biochemical and Molecular Research (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Microtubule and mitosis dynamics (2 papers). Alan T. Henley collaborates with scholars based in United Kingdom and Switzerland. Alan T. Henley's co-authors include Florence I. Raynaud, Paul Workman, Suzanne A. Eccles, Melanie Valenti, Alexis de Haven Brandon, Michelle D. Garrett, John Caldwell, Ian Collins, Ruth Ruddle and Rosemary Burke and has published in prestigious journals such as Journal of Medicinal Chemistry, Molecular Cancer Therapeutics and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Alan T. Henley

12 papers receiving 262 citations

Peers

Alan T. Henley
Jeffrey Tredup United States
Adriana Stroba Germany
Hillary L. Sturgis United States
Sachio Shibata Japan
A. Jestel Germany
Zhizhou Fang Germany
David R. Goode United States
Jesús Vázquez Spain
Mark A. Bobko United States
Chau Almaden United States
Jeffrey Tredup United States
Alan T. Henley
Citations per year, relative to Alan T. Henley Alan T. Henley (= 1×) peers Jeffrey Tredup

Countries citing papers authored by Alan T. Henley

Since Specialization
Citations

This map shows the geographic impact of Alan T. Henley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan T. Henley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan T. Henley more than expected).

Fields of papers citing papers by Alan T. Henley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan T. Henley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan T. Henley. The network helps show where Alan T. Henley may publish in the future.

Co-authorship network of co-authors of Alan T. Henley

This figure shows the co-authorship network connecting the top 25 collaborators of Alan T. Henley. A scholar is included among the top collaborators of Alan T. Henley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan T. Henley. Alan T. Henley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Pál, Ákos, Yasmin J. Asad, Ruth Ruddle, et al.. (2020). Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. Metabolomics. 16(4). 50–50. 3 indexed citations
2.
Kalber, Tammy L., P. Stephen Patrick, Angela Hayes, et al.. (2020). Peritumoral Delivery of Docetaxel‐TIPS Microparticles for Prostate Cancer Adjuvant Therapy. Advanced Therapeutics. 4(2). 2000179–2000179. 4 indexed citations
3.
Ang, Joo Ern, Ákos Pál, Yasmin J. Asad, et al.. (2017). Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics. 16(10). 2315–2323. 8 indexed citations
4.
Ang, Joo Ern, Yasmin J. Asad, Alan T. Henley, et al.. (2016). Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular Cancer Therapeutics. 15(6). 1412–1424. 16 indexed citations
5.
Hayes, Angela, N. Yi Mok, Manjuan Liu, et al.. (2016). Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution. Xenobiotica. 47(9). 771–777. 4 indexed citations
6.
Roberts, Jennie, et al.. (2016). Capillary Microsampling of Mouse Blood in Early Pre-Clinical Studies: A Preferred Alternative to Dried Blood Spot Sampling. Journal of Bioanalysis & Biomedicine. 8(2). 5 indexed citations
7.
Bavetsias, Vassilios, Yolanda Pérez-Fuertes, Patrick J. McIntyre, et al.. (2015). 7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent. Bioorganic & Medicinal Chemistry Letters. 25(19). 4203–4209. 13 indexed citations
8.
Bavetsias, Vassilios, Amir Faisal, Simon Crumpler, et al.. (2013). Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells. Journal of Medicinal Chemistry. 56(22). 9122–9135. 63 indexed citations
9.
Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations
10.
McHardy, Tatiana, John Caldwell, Kwai-Ming J. Cheung, et al.. (2010). Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt). Journal of Medicinal Chemistry. 53(5). 2239–2249. 67 indexed citations
11.
Smith, Nicola F., Angela Hayes, Karen James, et al.. (2006). Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Molecular Cancer Therapeutics. 5(6). 1628–1637. 23 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Tredup Breakdown of academic impact, for papers by Adriana Stroba Breakdown of academic impact, for papers by Hillary L. Sturgis Breakdown of academic impact, for papers by Sachio Shibata Breakdown of academic impact, for papers by A. Jestel Breakdown of academic impact, for papers by Zhizhou Fang Breakdown of academic impact, for papers by David R. Goode Breakdown of academic impact, for papers by Jesús Vázquez Breakdown of academic impact, for papers by Mark A. Bobko Breakdown of academic impact, for papers by Chau Almaden
Rankless by CCL
2026